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Emergence and potential transfer of antibiotic resistance in skin microorganisms is
of current concern in medicine especially in dermatology contexts where long term
treatment with antibiotics is common. Remarkably, non-antibiotic therapy in the form
of isotretinoin – a non-antimicrobial retinoid is effective at reducing or eradicating
the anaerobe Propionibacterium acnes which is causally involved in the complex
pathogenesis of Acne vulgaris. This study measured the extent of colonization of
P. acnes in patients with primary cystic or severe acne from three defined skin sites in
‘non-lesion’ areas before, during and after treatment with isotretinoin. Patients attending
acne clinics were investigated using standardized skin sampling techniques and the
recovery of anaerobic P. acnes from 56 patients comprising 24 females and 32 males
(mean age 22 years, age range 15–46 years) who were given a standard course of
isotretinoin (1 mg/kg/day) are reported. P. acnes cultured from the external cheek
surface of patients following treatment showed a significant reduction (1–2 orders of
magnitude) compared with their pre-treatment status. Interestingly, other distinct sites
(nares and toe web) failed to show this reduction. In addition, high levels of antibiotic-
resistant P. acnes were recorded in each patients’ skin microbiota before, during and
after treatment. In this study, microbial composition of the skin appears substantially
altered by isotretinoin treatment, which clearly has differential antimicrobial effects on
each anatomically distinct site. Our study confirmed that orally administered isotretinoin
shows good efficacy in the resolution of moderate to severe acne that correlates
with reductions in the number of P. acnes on the skin, including resistant isolates
potentially acquired from previous treatments with antibiotics. Our study suggests that
the role of tetracycline’s and macrolides, which are currently first line treatments in
dermatology, might be reserved for severe or life-threatening infections since current
antibiotic stewardship guidelines from medical departments no longer prescribe these
antibiotics for routine use.
Keywords: Acne vulgaris, skin microbiome, antibiotic resistance, isotretinoin treatment and Propionibacterium
acnes
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INTRODUCTION
Prolonged antibiotic use associated with long term acne
treatment regretably promotes multi-drug resistant strains of
many common members of the skin microbiota. Many of
the organisms involved are potential pathogens and represent
additional risk with increases of antibiotic use in healthcare
contexts (Miller et al., 1996; Levy, 2002; Dréno et al., 2004).
Therapeutic failure of some antibiotics to treat acne has been
reported, posing a problem for future management as antibiotic
resistance in P. acnes continues to evolve (Ross et al., 2001; Ayer
and Burrows, 2006). Isolates of P. acnes which have acquired
resistance to one or more of the antibiotics routinely used as
ﬁrst line treatment in acne (mutations in 16S and 23S mRNA)
are reported from both within and outside Europe (Leyden,
2001). Despite these concerns, the continuing low number of
research based publications in this area reﬂect the need for
understanding of local/national/international resistance status
of relevant organisms, so that treatment concensus can be
implemented (Walsh et al., 2016). There is a research need
for new and innovative therapies for acne to be targeted at
P. acnes but avoiding traditional antibiotics to resonate with
a re-education away from the heavy reliance on antibiotics
in practice worldwide. Alternatives such as bacteriophage for
targeting P. acnes are potential novel treatments for acne
(Jon´czyk-Matysiak et al., 2017).
The superﬁcial layers of the epidermis and the upper parts
of the hair follicles have a well-recognized speciﬁc microbiota,
which consists largely of micrococci (Staphylococcus epidermidis,
Micrococcus species), Corynebacteria and Propionibacterium spp.
(Yousif and Dabbagh, 2016). These are generally symbiotic and
rarely take on a pathogenic role. Recent evidence supports
the theory that the principal organism within the sebaceous
unit, the site of inﬂammation, is P. acnes (Fitz-Gibbon et al.,
2013). The complex multifactorial mechanisms that lead to the
eruption of acne have shown that P. acnes play a signiﬁcant
but as yet poorly understood role in the pathogenesis of the
disease. It survives in the superﬁcial layers and in sebaceous
elements of the skin and is the most prominent organism
involved in the complex pathogenesis of acne (Ayer and Burrows,
2006). Consequently, P. acnes is traditionally the major target
organism in acne for antibiotic therapy, but with primary
cystic or acne that has not responded, isotretinoin (13-cis-
retinoic acid) may be indicated (Andriessen and Lynde, 2014).
Although the mechanism of action is unknown, isotretinoin
unexpectedly exerts an antibacterial eﬀect on P. acnes and
correlates with clinical resolution of lesions (Gollnick et al.,
2003). The antimicrobial eﬀects of the retinoid may be due
to unexpected eﬀects relating to its multiple biological and
physiological activities in mammals (Fitz-Gibbon et al., 2013).
Amongst the readily available preparations, only systemic
isotretinoin appears to address all the causal factors of acne
(Guttman, 2000; Rigopoulos et al., 2010). The current thinking
is that isotretinoin decreases the oil produced by reducing the
size of the sebaceous glands, reduces follicular keratinisation by
increasing skin cell shedding and reduces the ductal and surface
P. acnes counts (Peck et al., 1982; Gollnick et al., 2003). No other
treatment appears to correct the keratinisation abnormality that
is key to treatment success (Millikan, 2009) and furthermore
eﬀects are found to persist following cessation of therapy to
varying degrees (Habif, 2003).
Unfortunately, a number of important side eﬀects are
associated with isotretinoin administration but can be avoided
in most patients by regular monitoring and blood tests (Ayer
and Burrows, 2006; Kaymak and Ilter, 2006). Following the
discovery that major malformations may occur in 25–30% of
fetuses exposed to isotretinoin (Lammer et al., 1985) there is
no doubt that miscarriages and premature births are associated
with the use of isotretinoin. However, this information has
been very much taken on board by the manufacturers who
raised awareness of the issue including a pregnancy-prevention
program (Mitchell et al., 1995). There is a very clear warning
label on isotretinoin packaging stating that it should not be used
by women of childbearing potential (The Centers for Disease
Control and Prevention [CDC], 2000) unless they are under the
care of a physician familiar with isotretinoin use (Atanackovic
and Koren, 1999). The manufacturers released the System to
Manage Accutane Related Teratogenicity (S.M.A.R.T) program
(Nutley, 1998) where all females must be screened for pregnancy
and have a conﬁrmed negative pregnancy test. Patients must
also give assurance that they will use two forms of pregnancy
prevention commencing 1 month before treatment is undertaken
and ending 1 month after treatment cessation. A pregnancy test
must be performed at each monthly visit and only 30 days’ supply
is prescribed. Once the S.M.A.R.T. letter of understanding is
completed, a qualiﬁcation sticker is aﬃxed to the prescription and
this is an absolute pre-requisite for the prescription to be fulﬁlled
(Liao, 2003). This system has now been replaced by iPLEDGE in
the United States of America (ipledgeprogram.com) which was
approved by the FDA in 2006. Despite the fact that isotretinoin is
the most eﬀective treatment in the dermatologist’s arsenal, these
rigorous pregnancy prevention programs and negative media
reports of the serious side eﬀects of isotretinoin has relegated it
to the bottom of the prescribing list and explains the reason that
isotretinoin is not always a ﬁrst line treatment.
Prescribing a suitable course of acne therapy is fraught with
diﬃculty from the clinician’s viewpoint. More than 100 treatment
regimens are available (Eady, 1998) and some of the evidence is
irrefutable when it comes to eﬃcacy, however, the sheer volume
of information probably leads, to an extent, to a failure to
exploit the appropriate research information. However, recently
many dermatologists have recognized isotretinoin as a valuable
treatment for patients with less severe, but scarring acne or that
which is resistant to oral antibiotics, in order to minimize the
psychological impact on these young patients (Rigopoulos et al.,
2010).
Around 13 million people worldwide have been treated with
isotretinoin since 1982 (Del Rosso, 2012). Isotretinoin can resolve
acne in 85% of patients after one course of treatment (Harper
and Thiboutot, 2003) and this helps to prevent scarring in
individuals with severe cystic (acne with cysts) or nodulocystic
acne (inﬂammatory acne with nodules and cysts). Isotretinoin
applied topically helps to reduce the systemic toxicity observed
during oral administration, but topical therapy is most suitable
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for mild to moderate cases, especially those which are comedonal
in nature, e.g., adapalene (a naphthoic acid derived retinoid)
(Ayer and Burrows, 2006).
These ﬁndings are in contrast to antibiotic treatment, which
follows a long-term pattern of repeat visits to the General
Practitioner oﬃce for new courses of treatment, as their skin
bacteria become resistant to each antibiotic prescribed in turn. It
is also worthy of note that prolonged antibiotic treatment is not
without its share of side eﬀects. For example, there is increasing
evidence of macrolide prescribing in pregnancy causing serious
harm to the unborn baby, including an increased risk of cerebral
palsy or epilepsy (Meeraus et al., 2015). Teratogenic risks to the
developing fetus from oxytetracycline have also been reported
(Czeizel and Rockenbauer, 2000).
During this study, the colonization of P. acnes from patients
with acne before, during and after treatment with isotretinoin was
assessed, determining both qualitative and quantitative recovery.
The antibiotic sensitivities of P. acnes were also studied, to
give an overall picture of the resistance status of local acne
patient’s skin microbiota, to help contribute to understanding the
local/national/international resistance status over time, so that
treatment concensus can be implemented.
MATERIALS AND METHODS
This study was carried out with permission and in accordance
with the recommendations of ethical guidelines and the ethics
committees of the University of Lincoln and United Lincolnshire
Hospital NHS Trust (on ﬁle) with written informed consent
from all subjects. All subjects gave written informed consent
in accordance with the Declaration of Helsinki. All chemicals
apart from where speciﬁed were purchased from Sigma–Aldrich
Company Ltd., (Dorset, United Kingdom). All media apart from
where speciﬁed were supplied by Oxoid Ltd., (Hampshire, United
Kingdom). The antibiotic-susceptible reference strains were used
throughout: P. acnes Type I ATCC 6919 and Type II ATCC
12930 (American Type Culture Collection, Manassas, VA, United
States).
Patient Inclusion
Patients who have failed to respond to antibiotics administered
during primary care treatment for acne were referred to Lincoln
County Hospital Dermatology Department for assessment. If
changes in antibiotic therapy did not resolve the skin condition
satisfactorily (Rigopoulos et al., 2010), or the acne was graded as
‘severe’ or ‘very severe’ according to the American Academy of
Dermatology Consensus Conference ﬁndings (Pochi et al., 1991),
patients following the appropriate precautions, were treated with
isotretinoin and included in the present study. Isotretinoin is
available in tablet form and administered orally.
The present study involved the recovery and analysis of
skin organisms from 56 patients comprising 24 females and 32
males (mean age 22 years, age range 15–46 years) who were
selected for a standard course of isotretinoin (1 mg/kg/day)
(Roche, Hertfordshire, United Kingdom). All patients completed
a lifestyle questionnaire and gave informed consent.
Since P. acnes is so common on the skin, gloves were
worn during collection and processing of all samples to ensure
that there was no cross-contamination between patient and
collector. This also provided protection to the collector from
any pathogens being retrieved from the nares for example
Streptococcus pneumonia (Oh et al., 2012).
Methodology
Representative samples of skin microbiota were recovered from
three sites: the left cheek, nares and toe web of the left foot
using a standardized procedure during an 18-month period.
The left cheek of each patient was sampled, as this is the most
common area for acne to present and therefore the main target of
isotretinoin therapy. The nares were considered to be of interest
as a reservoir for resistant organisms including Staphylococcus
spp. (Williams, 1963; Ross et al., 2001; von Eiﬀ et al., 2003;
Sakwinska et al., 2009). The anatomically distant region of the toe
web represents an area of skin which is clothed, so has a higher
temperature and humidity, as well as fewer sebaceous glands, a
reduced sebum concentration and generally lower numbers of
P. acnes (McGinley et al., 1980; Grice and Segre, 2011).
Sample collection
Precautions were taken to reduce contamination risks and to
reduce variance by observing aseptic technique and using powder
free latex gloves throughout. The clinical samples were taken
at four sampling times: t0 – start of treatment; t1 (8 weeks
into treatment – half way through the treatment to correlate
with observable clinical improvements); t2 (end of treatment); t3
(1-month post treatment), at which point there should be no trace
of the administered drug in the patient given that the elimination
half-life of isotretinoin is approximately 22 h (Layton, 2016).
According to Dai et al. (1989), after 1 month isotretinoin cannot
be detected in the circulation.
Wash solution for sampling
All samples were collected using a standard wash solution as
developed by Williamson and Kligman (1965) and Dawson et al.
(1989). Full-strength solution: 0.1% Triton X-100 in 0.075 M
phosphate buﬀer at pH 7.9 and half-strength solution: 0.05%
Triton X-100 in 0.0375 M phosphate buﬀer at pH 7.9 were used.
Sampling of left cheek
To sample the large ﬂat area of the cheek the scrub method
described by Williamson and Kligman (1965) was used as a
quantitative method. Brieﬂy, 1 mL of full-strength scrub solution
was applied to the cheek by pipetting into a sterile metal tube held
against the skin surface. The skin was gently rubbed using a sterile
non-charcoal swab. The solution was pipetted back into a sterile
Universal bottle, and the swab was placed into the liquid. This
process was repeated, and 2 mL of pooled solution and swab in a
bottle was transported back to the laboratory.
Sampling of nares
A sterile non-charcoal swab was moistened in full strength wash
solution. This was carefully inserted about 1 cm into the nostril
and whilst applying slight pressure against the mucosal surface,
the swab was rotated six times in each direction according to
the method of Coates et al. (1997). The patient under close
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supervision carried out this procedure. The process was repeated
for the other nostril, and both swabs were placed in 1 mL of
full-strength wash solution.
Sampling of toe web
A sterile non-charcoal swab moistened in full strength wash
solution, was rubbed ﬁrmly up and down between the big and
second toe and twisted around in the toe web (Coates et al.,
1997). The swab was placed in a ‘Universal’ bottle in 1 mL of
full-strength wash solution.
Bottles containing swabs from the left cheek, nares and toe web
were subjected to vigorous mixing for 30 s to release any bacteria
into suspension and the swabs were discarded (Coates, 2000).
Primary isolation
Recovered wash samples from patients were plated within 24 h
of collection. Primary isolation and quantiﬁcation of P. acnes for
each sample was achieved by inoculation onto Tryptone Yeast
Extract glucose (TYEg) agar (Ross et al., 1997; Coates et al., 2002)
containing furazolidone at a rate of 2 µg mL−1 for the inhibition
of Staphylococcus growth (Ross et al., 2003; Rottboell et al., 2015).
Growth was obtained by incubation under anaerobic conditions
at 34◦C for 4–7 days in Genboxes (BioMérieux, Marcy l’Etoile,
France). Any colonies present on the agar following incubation
were putatively identiﬁed as Propionibacterium spp.
Selection of antibiotic-resistant strains
Antibiotics erythromycin (E), clindamycin (C), and tetracycline
(T) were added to the basal medium at the following
concentrations: erythromycin (TYEg-E) (0.5 µg mL−1),
clindamycin (TYEg-C) (0.5 µg mL−1), and tetracycline (TYEg-
T) (5 µg mL−1) (Brown and Poston, 1983; Eady E.A. et al., 2003;
Ross et al., 2003). Appropriate concentrations were obtained
from the Clinical and Laboratory Standards Institute (CLSI,
1997).
Quantification of organisms within samples
Decimal serial dilutions were prepared following collection
from all three sites, using half-strength wash solution as the
diluent. Once prepared 20 µl aliquots of each dilution for all
of the samples were used to prepare viable counts (Miles et al.,
1938). Each dilution was plated in triplicate. The total counts
for sensitive and resistant populations at diﬀerent sites were
estimated by inoculating four TYEg plates for each sample, with
and without antibiotics, and any resulting bacterial colonies were
counted following incubation.
Statistical analysis of plate counts
Although some patients did not attend all of their hospital visits,
the data for all 56 patients was analyzed and processed for the
purposes of this study. All relevant variables were subjected
to two-way Analysis of Variance (ANOVA), Hair et al. (2006)
compiled separately for each of the three sampled anatomical
sites. The ANOVA technique was selected to detect diﬀerences in
two or more population means. It does not highlight which of the
tested populations means are diﬀerent, but establishes whether
there is/or is not a signiﬁcant diﬀerence between the population
means being compared. SPSS version 23, MINITAB Release 14
andMS Excel 2013 were used for all analysis and data processing.
Post hoc tests of statistical significance
If the resultant F-test by ANOVA were signiﬁcant at least at the
5% level (P < 0.05) then the Null hypothesis would be rejected
in favor of the Alternative Hypothesis that one or more of the
populationmeans being tested is/are signiﬁcantly diﬀerent. If this
is shown to be the case then a post hoc test of these diﬀerences
in mean values was applied using a Multiple Range Test. This
test uses the standard deviation of these means and a Q-value
obtained from “The Studentized Range” table, dependent on
degrees of freedom and number of groups. Thus a P-value is
not generated during this test, signiﬁcance is determined if the
compared mean values exceed the Q× SD value.
Morphological and biochemical tests
Classical phenotypic identiﬁcation of bacteria was undertaken
including Gram staining (Wilson, 2000) and Analytical Proﬁle
Index tests (20A anaerobes) BioMérieux (Marcy l’Etoile, France).
RESULTS
Patient Sampling and Retention
Table 1 shows details of patient visits. The data for all 56 patients
were analyzed and any incomplete data taken into account during
statistical analysis and processing. Of the patients who attended
regularly, there was a distinct pattern of improvement of their
condition. By the time they visited for their t1 appointment
(8 weeks) their skin was very dry, so much so that most of
them had Vaseline on their lips. Dryness of the skin and lips
is a known common side eﬀect of treatment with isotretinoin
(McLane, 2001). There was some improvement in most cases.
Some patients reported that their condition had worsened (acne
ﬂare) at ﬁrst, but had since improved (Goulden, 2003). By
the t2 appointment (16 weeks), their condition had improved
dramatically. The face had a slightly pink appearance, probably
due to the peeling eﬀect on the skin. The acne was completely
resolved as assessed during their t3 appointment in all patients
that attended. Some patients were left with small ﬂat, dark patches
of skin known as pseudo-scars or macules (Poli et al., 2001)
which normally fade over 6 months. There was a noticeable
improvement in self-esteem in all patients.
The results obtained for microbiology in the present study
correlate well with a previous two-center study carried out
between 1996 and 1999 in Leeds, United Kingdom and
Philadelphia, United States (Coates et al., 2005). The studies
were designed to be similar by using the same standard dose of
TABLE 1 | Summary of patient sampling and retention.
Number of Patients
Total recruited 56
Attended only 1 consultation 6
Did not complete the course 7
Completed treatment but did not attend all appointments 7
Did not attend follow-up 14
Completed all treatment and attended follow-up 22
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isotretinoin; the same standardized swabbing procedures and the
same sampling times (0, 8, and 12 weeks) as well as identical
isolation techniques, media and antibiotic concentrations.
Quantification of Bacteria from the Skin
of Patients
Figure 1 shows the number of bacteria at each skin site (data
transformed by log10 to achieve Normality assumption). The
distribution of isolates in the 56 patients studied are presented as
mean CFUs per mL across the cohort. Error bars represent 95%
conﬁdence interval.
Microbiota of the Left Cheek – P. acnes Colonization
Levels Decrease as Treatment Progresses
Figure 1 demonstrates a substantial reduction in the number
of skin bacteria recovered from the cheek surface as treatment
progresses compared to pre-treatment status for the 56 acne
patients. These organisms are P. acnes with erythromycin,
clindamycin, and tetracycline resistant colonies included.
Statistical analysis for left cheek
After performing ANOVA (Table 2) followed by a Multiple
Range Test (Table 3) it was shown that there was no signiﬁcant
diﬀerence between the numbers of organisms present at t0
and t1 (critical value not exceeded, thus p > 0.05) but
the number of organisms recovered between t1 and t2 was
signiﬁcant (P < 0.05). There was no signiﬁcant diﬀerence
between the numbers of organisms present between t2 and
t3. The mean number of P. acnes grown on non-antibiotic
plates is as expected signiﬁcantly higher (7.78 × 102 CFU/mL)
than those grown in the presence of antibiotics erythromycin
(1.30 × 102 CFU/mL), clindamycin (3.71 × 101 CFU/mL) and
tetracycline (1.52× 102 CFU/mL). The test for signiﬁcance, again
using the Multiple Range Test, shows values that exceeded the
critical value and indicate that p < 0.05. The mean numbers of
P. acnes resistant to erythromycin, clindamycin and tetracycline
were not signiﬁcantly diﬀerent from each other and all declined
at a rate proportional with the non-antibiotic plates.
Microbiota of the Nares – P. acnes Colonization
Levels Decrease as Treatment Progresses
Figure 1 shows that the number of organisms recovered from
within the nares decreased (approximately 1 log between t0
and t2) as treatment progressed. There seems to be minimal
eﬀect on the proportion of resistant organisms within the
decreasing population, as growth on all media has decreased at
approximately the same rate.
Statistical analysis for nares
Statistically there was a signiﬁcant decrease in the number of
organisms between t0 and t1, and between t1 and t2. A signiﬁcant
recovery in the number of organisms post treatment (between t2
and t3) could not be shown (Table 3).
Media: The number of presumptive P. acnes isolated on
non-antibiotic plates was signiﬁcantly higher than the numbers
isolated in the presence of antibiotics erythromycin, clindamycin
and tetracycline, furthermore the number of organisms recovered
from plates impregnated with antibiotics was not signiﬁcantly
diﬀerent from each other (Figure 1).
Microbiota of the Toe Web – P. acnes Colonization
Levels Increase as Treatment Progresses
Figure 1 demonstrates an increase in the number of organisms
recovered from the toe web as the treatment progresses compared
to pre-treatment status for the 56 acne patients.
Statistical analysis for toe web
There was no signiﬁcant change in the number of organisms
isolated between t0 and t1 but there was a signiﬁcant increase
in the number of organisms isolated between t1 and t2. There
was no signiﬁcant change in the number of organisms isolated
between t2 and t3 in the toe web (Table 3). There was no
signiﬁcant diﬀerence in the number of P. acnes isolated on non-
antibiotic plates and erythromycin plates. However, the number
of organisms isolated on non-antibiotic and erythromycin
plates were signiﬁcantly higher than the number isolated from
clindamycin and tetracycline plates. Furthermore, the number
of isolates showing resistance to clindamycin was signiﬁcantly
higher than the numbers isolated from tetracycline plates
(Table 3).
The present study reports the recovery and analysis of skin
organisms from patients with a mean age of 22 years (range 15–
46 years), whereas the mean age in Leeds was 23 years (range
15–39) and mean age in Philadelphia was 25 years (range 13–
49 years). The major diﬀerences between studies was that Coates
and co-workers only included patients that were found to be
heavily colonized with antibiotic-resistant anaerobic organisms
(>103 CFU cm−2) and the t3 sampling was carried out 12 weeks
after the cessation of therapy (week 28) and not 4 weeks after
(week 20) as in the present reported study.
DISCUSSION
Our ﬁndings were generally in very good agreement with the two
previous major studies on this topic, reviewed by Coates et al.
(2005), suggesting an interesting international consensus of the
eﬀects of isotretinoin on skin microbiota of treated individuals.
In all three studies (Figure 2) it can be seen that the trend
is a decrease in bacteria during isotretinoin administration,
followed by an increase in numbers following cessation of
therapy. When comparing the studies, we observed that our
male patients were signiﬁcantly younger than the female patients
(Table 4) and that appointment attendance lessened as the
study progressed, i.e., Attendance recorded at the post treatment
visit was 78% in Leeds, 84% in Philadelphia and only 61% in
Lincoln.
Remarkably, although isotretinoin is not an antibiotic,
treatment appears to eﬀectively control or reduce P. acnes from
the facial skin of patients. Interestingly, the retinoid has a greater
diﬀerential eﬀect on the facial skin microbiota than on the other
sites tested. There is a signiﬁcant change between t0 and t3
particularly t1 and t2 which correlates with the reduction in
clinical symptoms. The reduction in bacterial numbers on the
cheek, but not in the nares or toe web, is sustained after treatment
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FIGURE 1 | General trend for bacterial numbers on the cheek, nares and toe web of participants in the Lincoln study. The distribution of Propionibacterium acnes of
56 patients are presented as mean CFUs (per square cm for left cheek/per mL for nares and toe web) across the cohort. The number of colonies isolated on TYEg
agar with and without antibiotics for the clinical cohorts during treatment. Antibiotics are represented by E-erythromycin; C-clindamycin; and T-tetracycline. The data
was transformed by log10. Error bars represent 95% confidence intervals.
TABLE 2 | Summary of p values from two way Analysis of Variance testing for
differences between sampling times and media types (with and without antibiotics)
for each of the three sites.
TYEg/TYEg-E/TYEg-C/TYEg-T antibiotic resistance
selection
Time Media
Cheek 4.9e-7 3.5e-4
Nares 1.2e-5 9.0e-6
Toe Web 2.6e-5 6.8e-6
has been completed, although the results fromCoates et al. (2005)
suggest that this reduction in P. acnes following treatment may be
transient (Figure 2). This is probably due to the fact that plasma
concentrations return to normal after 10 days (Cunliﬀe et al.,
1997) and that isotretinoin is cleared from the circulation after
1 month (Dai et al., 1989). The P. acnes population will then
begin to return and are found to be at pre-treatment levels within
2 months (Leyden and McGinley, 1982).
Figures 2, 3 summarize recovery data from the current study
with the two-center study in Leeds and Philadelphia (Coates et al.,
2005). When compared with the P. acnes isolated in the present
study, the quantitative reduction in resistant P. acnes is slightly
more pronounced in Leeds and Philadelphia (at t1) although the
general trend of the three centers is comparable.
Our study showed that a high proportion of the P. acnes
isolated from the skin microbiota was multiply antibiotic-
resistant. This was not surprising, since all patients included in
the study had been previously treated extensively with antibiotics.
However, the resistance of the P. acnes isolates did not always
correlate with antibiotics that had previously been prescribed
for each individual, suggesting that resistance was detected
without any obvious selective pressure. A possible source for
this resistance is that the bacteria acquired genetic elements
from other organisms in their environment, which will equip
them with protection against antibiotics that they have not
themselves previously encountered (van Hoek et al., 2011).
Although P. acnes resistance is mainly attributed to ribosomal
modiﬁcations, early studies by Ross et al. (2002) described
resistance conferred by the erm(X) gene, which may have
either been transferred from Corynebacterium on three separate
occasions into Propionibacterium acnes, avidum and granulosum;
or it may have been transferred between the Propionibacterium
spp. themselves. Another gene known as ermCD, is also described
as a gene which could potentially move between strains, but this
has been diﬃcult to prove in vivo and the genes described by Ross
are now thought to be non-transferable essential chromosomal
genes. Thus, since P. acnes resistance is mainly attributed
to ribosomal modiﬁcations, environmental or horizontal gene
transfer is not thought to be likely. The problem is thus a
twofold one of patients taking antibiotics which induce resistance
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TABLE 3 | Summary of significance identified using Multiple Range Tests for microbial isolations from anatomically distinct sites.
P. acnes
Time Media
t0 t1 t2 t3 TYEg TYEgE TYEgC TYEgT
Cheek t0 NS ∗ ∗ TYEg ∗ ∗ ∗
t1 ∗ ∗ TYEgE NS NS
t2 NS TYEgC NS
t3 TYEgT
Nares t0 ∗ ∗ ∗ TYEg ∗ ∗ ∗
t1 ∗ NS TYEgE NS NS
t2 NS TYEgC NS
t3 TYEgT
Toe t0 NS ∗ ∗ TYEg NS ∗ ∗
Web t1 ∗ ∗ TYEgE ∗ ∗
t2 NS TYEgC ∗
t3 TYEgT
KEY, ∗denotes significant difference. NS, no significant difference. Significant differences ∗ are found when ranges of results exceed the critical value and thus conclude a
p-value of <0.05.
FIGURE 2 | Comparison of general trends of bacterial numbers on the cheek from participants from Lincoln, Leeds and Philadelphia, United States. The distribution
of P. acnes from the cheek of patients are presented as mean CFUs per square cm across the cohort. The number of colonies isolated on TYEg agar with and
without antibiotics for the clinical cohorts during treatment. Antibiotics are represented by E-erythromycin; C-clindamycin; and T-tetracycline. The data was
transformed by log10. Data drawn from Coates et al. (2005).
over time and then those patients transferring their resistant
organisms to others (Simpson, 2001).
Combined erythromycin and clindamycin resistance was
demonstrated in P. acnes from 20% of acne patients in
1979 (Ross et al., 1997) and tetracycline resistance was ﬁrst
documented in 1980 (Ross et al., 1998). Traditionally long
term therapy with a limited number of antibiotics has been
customary in anti-acne therapy and implementation of better
usage policies was found to be slow to be taken up (Ross
et al., 1997). Our results in the present study may reﬂect slight
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TABLE 4 | Age and sex of patients sampled.
Age in yearsa
Source of
patients
Sex Number of
patients
(Percentage)
Range Mean (SD)
Lincoln Male 32 (57) 15–36 20.2
Female 24 (43) 16–46 24.8
Total 56 15–46 21.9
Leeds Male 44 (61) 15–39 21.5 (5.0)
Female 28 (39) 15–37 25.3 (6.4)
Total 72 15–39 23.0 (5.9)
Philadelphia Male 23 (37) 13–42 21.3 (7.2)
Female 39 (63) 15–49 26.3 (7.3)
Total 62 13–49 24.5 (7.6)
Key: aAge at entry into study. The average age of the acne sufferers seeking therapy
at the hospital clinic was 22 years in Lincolnshire (present study); 23 years in Leeds
and 24.5 years in Philadelphia (Coates et al., 2005).
improvements in prescribing habits within the dermatology
clinic.
It was considered that variance may have been introduced
from self-sampling of patients nares, however, research has
revealed that self-sampling of the nares, even when carried out
using written instructions and no supervision, is eﬀective for
bacterial collection. When compared with investigator collection
there was 93% agreement (van Cleef et al., 2012). Our collections
were carried out under close supervision, following careful
instruction to minimize any variance. The microbiota from the
nares was shown to respond diﬀerently across all three studies
(Figures 3, 4). Although in the present study, numbers of
P. acnes start an order of magnitude higher than those from the
cheek, during treatment with isotretinoin there was a signiﬁcant
reduction in numbers and then a recovery in population once
treatment was completed. When compared with isolations of
P. acnes from nares (Figure 3) the reduction in resistant P. acnes
isolated at t1 are proportionally less than that of P. acnes at t2
in the nares. Again, the general trend of the three studies is
comparable. Given that the nares are a reservoir for antibiotic
‘resident’ resistant organisms, it is with interest that we note
the similarities between the data shown in Figure 3. There is
a clear, signiﬁcant diﬀerence between the organisms isolated on
TYEg (without antibiotics) and the lower numbers of organisms
showing resistance to the antibiotics. We are also aware that in
the present study of the left cheek and nares, there does not seem
to be a clear diﬀerence between the resistance rates for any of
the antibiotics tested (Figure 1). In contrast, comparisons of the
two previous studies, erythromycin and clindamycin resistance
was slightly higher than in our study and tetracycline resistance
was clearly lower (Figure 4). At that time, the authors expressed a
need to reduce resistance rates, particularly to erythromycin and
clindamycin (Coates et al., 2005). Several years on, erythromycin
and clindamycin resistance appears in our study to be slightly
less than previously reported and is now consistent with the
tetracycline resistance rates (Figure 1). Persistence of drug
resistance is probably a reﬂection of tetracycline remaining the
drug of choice for oral acne treatment, whilst erythromycin
and clindamycin remain the treatment of choice for topical
application despite the fact that many authors caution entirely
against the use of antibiotics for acne therapy (Dreno et al.,
2014; Walsh et al., 2016). Inevitably, antibiotic therapy aﬀects
the ecology of the skin microbiota of the acne patient, as well
as the possible mutation and evolution of the P. acnes on their
skin and that of their close contacts (Eady, 1998; Eady A.E. et al.,
2003).
Multiply antibiotic-resistant organisms amongst dermatology
patients have been well documented during the last three decades,
but the volume of research literature and choices of acne therapy
means that it remains a diﬃcult and confusing task when
choosing a treatment regime (Eady, 1998). It is noteworthy that
outside of dermatology departments, tetracycline’s are seldom
used as the ﬁrst choice treatment for medical infections, as
the spread of resistance continues to reduce their eﬀectiveness.
Given the serious infections that macrolides are employed to
control, there is also increasing concern about resistance to the
macrolides. The spectrum of bacteria against which macrolides
are active is similar to that of penicillin and they were historically
of signiﬁcant value in cases of penicillin allergy. However, the
resistance status of macrolides in areas of medicine such as
dentistry have meant that their usefulness is outdated (Becker,
2013).
Microbiota from the toes (Figure 1) has not previously
been investigated in acne studies, but in the present study
they were sampled (as controls) and interestingly showed no
reductions in the bacterial population over the entire sampling
time. Moreover, the P. acnes numbers actually appear to increase
during treatment. This probably reﬂects the environmental
conditions of the toe web site and may reﬂect the importance of
dryness as a factor in the eﬀect of isotretinoin induced changes
in numbers of bacteria on skin. The presence of resistant P. acnes
in the toe web varied considerably more than was seen on either
the cheek or nares. Erythromycin resistance was most prevalent;
although clindamycin resistance was signiﬁcantly lower and
tetracycline resistance lower still (Figure 1).
The focus of this study was the reduction of P. acnes. The
systemic uptake of isotretinoin may aﬀect the ecosystem of the
skin in such a way that other skin microbes are also aﬀected.
Leyden et al. (1986) reported that important qualitative and
quantitative changes occur amongst the skin bacteria during
isotretinoin therapy, resulting in a reduction of P. acnes and the
Gram-negative bacteria, whilst an increase in the numbers of
S. aureus was observed.
Overall, the reduction in P. acnes numbers in this study is
likely to be mediated through alteration of the skin nutritional
microenvironment. McGinley et al. (1978, 1980) noted that
P. acnes were recovered in higher numbers where the skin
had a high number of sebum-producing sebaceous glands (for
example the facial skin) but also that many other factors play
a role in the numbers and types of bacteria on the skin
of the human. Aly and Maibach (1977) found that moisture
rich areas which had high numbers of eccrine sweat glands
including the feet, support higher numbers of bacteria. The
composition and numbers of the bacterial population of the
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FIGURE 3 | Comparison of general trends of bacterial numbers on the nares from participants from Lincoln, Leeds and Philadelphia, United States. The distribution
of P. acnes from the nares of 56 patients are presented as mean CFUs per mL across the cohort. The number of colonies isolated on TYEg agar with and without
antibiotics for the clinical cohort during treatment. Antibiotics are represented by E-erythromycin; C-clindamycin; and T-tetracycline. The data was transformed by
log10. Data drawn from Coates et al. (2005).
FIGURE 4 | Comparison of bacterial resistance status in the nares of participants from Lincoln, Leeds and Philadelphia, United States. The distribution of P. acnes
from the nares of patients are presented as mean CFUs per mL across three cohorts. The number of colonies isolated on TYEg agar with and without antibiotics for
the clinical cohort during treatment. Antibiotics are represented by E-erythromycin; C-clindamycin; and T-tetracycline. The data was transformed by log10. Error bars
represent 95% confidence intervals. Leeds and Philadelphia data drawn from Coates et al. (2005).
foot may be permanently increased due to the combined
eﬀect of increased numbers of sweat glands and the extent of
anaerobiosis.
Overall, this study indicates an international consensus on
the anti-P. acnes eﬀect of isotretinoin in acne treatment and
in addition that P. acnes resistance is maintained on the skin
of patients without obvious selective pressure from antibiotics.
The study strongly suggests that the microbial ecology of
human skin is substantially altered by isotretinoin treatment and
diﬀerent cutaneous micro-environmental conditions develop at
each anatomically distinct site – our analysis shows previously
unreported data with diﬀerential eﬀects on toe webs compared
with two other anatomical sites. The importance of P. acnes
ecology in the assessment of antibacterial eﬀects of non-
antibacterial treatments is highlighted and the importance of
including as many diverse sites for sampling human skin as
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possible when quantifying microbes and correlating with clinical
outcomes.
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